The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings ...
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ...
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that ...
A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer. Methods: A phase I, open-label, single-arm, ...
BOSTON--(BUSINESS WIRE)--Karuna Pharmaceuticals, Inc. (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and ...
Feb. 4 (UPI) --People in the United States can save up to 40% on prescription drug costs by switching to different formulations of the same medication, when available, a study published Friday by JAMA ...
CHICAGO--(BUSINESS WIRE)-- Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg ...
Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days. If you have the appropriate software installed, you can download article citation data to the citation manager of your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback